Please login to the form below

Not currently logged in
Email:
Password:

VX-135

This page shows the latest VX-135 news and features for those working in and with pharma, biotech and healthcare.

Gilead files oral hepatitis C drug sofosbuvir in US

Gilead files oral hepatitis C drug sofosbuvir in US

However, BMS has recently signed a deal with Vertex Pharmaceuticals to partner on a clinical investigating a combination of the BMS candidate daclatasvir and Vertex' uridine nucleotide analogue VX-135.

Latest news

  • BMS and Vertex partner on oral hepatitis treatment BMS and Vertex partner on oral hepatitis treatment

    VX-135 is a uridine nucleotide analogue that, like BMS-986094, is designed to affect the NS5B polymerase to inhibit the replication the hepatitis C virus. ... GSK2336805. In addition, Vertex is planning to test the use of VX-135 along with Incivek

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Pharma index map
The 2019 CPhI Pharma Index Report
Examining this year’s industry performance...
Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...

Infographics